Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 226 to 240 of 436 results for cardiovascular disease

  1. Upadacitinib for treating moderately to severely active ulcerative colitis (TA856)

    Evidence-based recommendations on upadacitinib (Rinvoq) for treating moderately to severely active ulcerative colitis in adults.

    Technology appraisal guidance
    Published
    4 January 2023
    View recommendations

    Sections for TA856

  2. What is the clinical effectiveness and rate of adverse events of statin therapy using atorvastatin 20 mg per day compared with atorvastatin 40 mg per day and atorvastatin 80 mg per day in people without established CVD?

    prevention of CVD and should be recommended for those at 10% risk of cardiovascular events as assessed using the QRISK2 calculator....

    Research recommendation
    Published
    9 June 2015

  3. Venetoclax with rituximab for previously treated chronic lymphocytic leukaemia (TA561)

    Evidence-based recommendations on venetoclax (Venclyxto) with rituximab for previously treated chronic lymphocytic leukaemia in adults.

    Technology appraisal guidance
    Published
    27 February 2019
    View recommendations

    Sections for TA561

  4. What is the clinical and cost effectiveness of levothyroxine (T4) and liothyronine (T3) combination therapy compared with T4 alone for people with hypothyroidism whose symptoms have not responded sufficiently to T4 alone? Does DiO2 polymorphism affect the response to combination therapy with T4 and T3?

    adults unless contraindicated (adults over 65 or with a history of cardiovascular disease). Although evidence about dosing was very...

    Research recommendation
    Published
    10 February 2020

  5. What is the improvement in the cost-effectiveness metrics for statin therapy in reducing CVD that can be obtained when using a complete individual patient-based outcomes meta-analysis data set compared with using published outcomes data?

    data. Source guidance details Comes from guidance Cardiovascular disease: risk assessment and reduction, including lipid modification

    Research recommendation
    Published
    9 June 2015

  6. Upadacitinib for treating active ankylosing spondylitis (TA829)

    Evidence-based recommendations on upadacitinib (Rinvoq) for treating active ankylosing spondylitis that is not controlled well enough with conventional therapy in adults.

    Technology appraisal guidance
    Published
    30 September 2022
    View recommendations

    Sections for TA829

  7. What is the effectiveness of age alone and other routinely available risk factors compared with the formal structured multifactorial risk assessment to identify people at high risk of developing CVD?

    risk. Source guidance details Comes from guidance Cardiovascular disease: risk assessment and reduction, including lipid modification

    Research recommendation
    Published
    9 June 2015

  8. Targeted-release budesonide for treating primary IgA nephropathy (TA937)

    Evidence-based recommendations on targeted-release budesonide (Kinpeygo) for treating primary immunoglobulin A (IgA) nephropathy in adults.

    Technology appraisal guidance
    Last updated
    9 October 2025
    View recommendations

    Sections for TA937

  9. What are the long-term outcomes of different management strategies for primary hyperparathyroidism? Which strategies are most cost effective?

    knowledge and experience, the committee agreed that the risk of recurrent disease after successful parathyroid surgery is very low and...

    Research recommendation
    Published
    25 October 2019

  10. What is the clinical and cost effectiveness of treatment (antithyroid drugs or radioactive iodine) for improving long-term health outcomes for people with subclinical hyperthyroidism?

    hyperthyroidism is persistent and appears to be caused by intrinsic thyroid disease. However, the committee noted that there is...

    Research recommendation
    Published
    10 February 2020

  11. VIDAvision for lung volume analysis in emphysema (MIB148)

    NICE has developed a medtech innovation briefing (MIB) on VIDAvision for lung volume analysis in emphysema .

    Medtech innovation briefing
    Published
    5 June 2018

  12. Mifamurtide for the treatment of osteosarcoma (TA235)

    Evidence-based recommendations on mifamurtide (Mepact) for treating osteosarcoma in people aged 2 to 30 years.

    Technology appraisal guidance
    Published
    26 October 2011
    View recommendations

    Sections for TA235

  13. Daratumumab in combination for treating newly diagnosed systemic amyloid light-chain amyloidosis (TA959)

    Evidence-based recommendations on daratumumab (Darzalex) for newly diagnosed systemic amyloid light-chain amyloidosis in adults.

    Technology appraisal guidance
    Published
    27 March 2024
    View recommendations

    Sections for TA959

  14. What is the efficacy and safety of COVID-specific antiviral drugs in combination with other COVID-specific antiviral drugs or COVID-specific neutralising monoclonal antibodies in people who do not need supplemental oxygen and are within 7 days of symptom onset?

    severe COVID-19 disease, including (but not limited to): • aged 60 or over• immunosuppression• obesity• hypertension• chronic lung...

    Research recommendation
    Published
    9 March 2022

  15. What is the efficacy and safety of remdesivir for people who have been vaccinated against COVID-19?

    severe COVID-19 disease, including (but not limited to): • aged 60 or over• immunosuppression• obesity• hypertension• chronic lung...

    Research recommendation
    Published
    9 March 2022